Program
Autologous Anti-CD19/CD20 CAR-T Cells KITE-363
Its studies are mostly in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · Lymphoma, B-Cell · Lupus Nephritis, led by Gilead Sciences.
Drug pageAutologous Anti-CD19/CD20 CAR-T Cells KITE-363: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.Furthest: phase 2, since Jul 26, 20213 company-led studies, 3 open or runningNext primary completion: Feb 2030 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Gilead Sciences | 33 open or running | phase 2since Jul 26, 2021 | Jul 26, 2021 | Feb 2030phase 2 · NCT04989803 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 26, 2021First study: phase 2 study in Relapsed and/or Refractory B-cell LymphomaFirst studyNCT04989803 · 247 enrolled · United States, Australia, Canada and more
- Jun 18, 2025Phase 1 study in Lupus Erythematosus, SystemicNCT07038447 · 52 planned · United States, Australia, Canada and more
- Dec 12, 2025Phase 1 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNCT07304154 · 57 planned · United States, Australia, Canada
- Sep 28, 2026Primary completion moved from 2029-07 to 2030-09Date moved laterphase 1 · +14 months · NCT07038447
- Nov 17, 2026Primary completion moved from 2029-06 to 2031-12Date moved laterphase 1 · +30 months · NCT07304154
Ahead
- Feb 2030Primary completion: phase 2 study in Relapsed and/or Refractory B-cell LymphomaNCT04989803
- Sep 2030Primary completion: phase 1 study in Lupus Erythematosus, SystemicNCT07038447
- Dec 2031Primary completion: phase 1 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNCT07304154
TargetBeta
“A preparation of autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) specific for the two tumor-associated antigens (TAAs) cluster of differentiation 19 (CD19) and CD20, ”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| rondecabtagene autoleucelrule | lyell-immunopharma-inc | phase 3 | 2 |
| zamtocabtagene autoleucelrule | miltenyi-biomedicine-gmbh | phase 2 | 8 |
| prizloncabtagene autoleucelrule | AbelZeta | phase 2 | 2 |
| GSK5926371 | GlaxoSmithKline | phase 2 | 2 |
| Allogeneic Anti-CD19/CD20 CAR T-cells AVC-203rule | avencell-therapeutics-inc | phase 2 | 1 |
| CT204V-CD19 × CD20rule | AstraZeneca | phase 2 | 1 |
| HB2198rule | hinge-bio | phase 1 | 1 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07304154Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Australia, Canada | 1 | Recruiting | Dec 2031 | 57 |
| NCT07038447Lupus Erythematosus, Systemic · United States, Australia, Canada and more | 1 | By invitation | Sep 2030 | 52 |
| NCT04989803Relapsed and/or Refractory B-cell Lymphoma · United States, Australia, Canada and more | 2 | Active, not recruiting | Feb 2030 | 247 |
How it is read
Names in the registry
- “KITE-363”, 3 entries
Conditions, from the studies’ own filings
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, 1 study
- Lymphoma, B-Cell, 1 study
- Lupus Nephritis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.